Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France

C. CHAIGNOT ; M. ZUREIK ; G. REY ; R. DRAY-SPIRA ; J. COSTE ; A. WEILL | 2018
Dans Pharmacoepidemiology and Drug Safety (Vol.27, n°11, November 2018) Article : Périodique

PURPOSE: Baclofen is widely used off-label for alcohol use disorders (AUD) in France, despite its uncertain efficacy and safety, particularly at high doses. This study was designed to evaluate the safety of this off-label use compared to the mai[...]

Plus d'info

Ajouter à la sélection

Lien externe